1. In Vivo
  2. >>Outlook

Financial Market Conditions Still Choppy As Rising Tide Has Yet To Lift All Ships

Some Boats Still Need To Sink Ahead Of Greater Gains

 
• By Mandy Jackson

Venture capital funding is up, and initial and follow-on public offerings are growing, but the building wave of investment in biopharma has not reached all companies.

Investment in biopharmaceutical companies has increased in 2024 relative to 2022 and 2023, when initial public offerings fell from record levels followed by a drop in venture capital funding, but the rising biotechnology tide has not lifted all ships in the sector.

While continued gains are expected as this year ends and 2025 begins, the wave of capital flowing into the sector still needs to wash away some sinking ships

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook

More from Market Intelligence

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.